Drugs against defined drivers (e.g., EGFR) offer new options for patients with advanced or recurrent OSCC, while immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 inhibitors, have shown encouraging clinical activity by reinvigorating anti-tumor immune responses. The gene discussed is PDCD1; the disease is neoplasm.